This study revealed that pirfenidone, a therapeutic agent used in the treatment of IPF, acted protectively against the inhibitory effect of TGF-β on vascular endothelial network formation, which plays an important role in promoting the development of fibrotic tissue. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.